AveXis Inc is a clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate is AVXS-101.
![Avexis logo](/files/LOGO/1652923-AVXS.png)
Company profile
Ticker
AVXS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
6 Jun 18
15-12B
Securities registration termination
4 Jun 18
EFFECT
Notice of effectiveness
23 May 18
CT ORDER
Confidential treatment order
16 May 18
S-8 POS
Registration of securities for employees (post-effective amendment)
15 May 18
POS AM
Prospectus update (post-effective amendment)
15 May 18
8-K
Completion of Acquisition or Disposition of Assets
15 May 18
25-NSE
Exchange delisting
15 May 18
SC 14D9/A
Tender offer solicitation (amended)
15 May 18
SC TO-T/A
Third party tender offer statement (amended)
15 May 18
Latest ownership filings
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|